Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valeria Solozobova

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Life Science Alliance|September 28, 2023
TRIM25 targets p300 for degradationSeham Elabd, Eleonora Pauletto, Valeria Solozobova, et al.
ACS Chemical Biology|September 10, 2021
Development of a Benzothiazole Scaffold-Based Androgen Receptor N-Terminal Inhibitor for Treating Androgen-Responsive Prostate CancerNane C Kuznik, Valeria Solozobova, Nicole Jung, et al.
Cancer Research Communications|July 31, 2023
Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer TherapyMengwu Pan, Valeria Solozobova, Nane C Kuznik, et al.
Iscience|April 28, 2022
A chemical probe for BAG1 targets androgen receptor-positive prostate cancer through oxidative stress signaling pathwayNane C Kuznik, Valeria Solozobova, Irene I Lee, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Life Science Alliance|September 28, 2023
TRIM25 targets p300 for degradationSeham Elabd, Eleonora Pauletto, Valeria Solozobova, et al.
ACS Chemical Biology|September 10, 2021
Development of a Benzothiazole Scaffold-Based Androgen Receptor N-Terminal Inhibitor for Treating Androgen-Responsive Prostate CancerNane C Kuznik, Valeria Solozobova, Nicole Jung, et al.
Cancer Research Communications|July 31, 2023
Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer TherapyMengwu Pan, Valeria Solozobova, Nane C Kuznik, et al.
Iscience|April 28, 2022
A chemical probe for BAG1 targets androgen receptor-positive prostate cancer through oxidative stress signaling pathwayNane C Kuznik, Valeria Solozobova, Irene I Lee, et al.
Pageof 1